Want to see ASH full AI Analyst Report?
Revenue by Segment
Shows how much revenue each of Ashland’s business units contributes, revealing the company’s product and market mix and whether growth is broad-based or driven by a few segments. Helps assess diversification, concentration risk, and which lines are likely to sustain future top-line growth.Revenue mix is shifting toward Life Sciences and Personal Care as the primary growth engines while Specialty Additives has lagged after its peak—Intermediates recovered modestly. That mix supports top-line momentum, but plant disruptions and lower fixed-cost absorption (notably Hopewell) have kept EBITDA soft; management is banking on pricing realization and manufacturing fixes to drive a Q4 profit step-up, yet Specialty Additives’ weak profitability remains the biggest downside risk to achieving the midpoint of reaffirmed EBITDA guidance.
Date | Eliminations | Life Sciences | Personal Care | Speciality Additives | Intermediates |
|---|---|---|---|---|---|
Jun 30, 2026 | -$11.00M | $180.00M | $155.00M | $136.00M | $37.00M |
Mar 31, 2026 | -$9.00M | $172.00M | $150.00M | $134.00M | $35.00M |
Dec 31, 2025 | -$9.00M | $139.00M | $123.00M | $102.00M | $31.00M |
Sep 30, 2025 | -$11.00M | $173.00M | $150.00M | $131.00M | $34.00M |
Jun 30, 2025 | -$10.00M | $162.00M | $147.00M | $131.00M | $33.00M |
Mar 31, 2025 | -$10.00M | $172.00M | $146.00M | $134.00M | $37.00M |
Dec 31, 2024 | -$11.00M | $134.00M | $134.00M | $115.00M | $33.00M |
Sep 30, 2024 | -$11.00M | $193.00M | $161.00M | $143.00M | $35.00M |
Jun 30, 2024 | -$12.00M | $195.00M | $175.00M | $150.00M | $36.00M |
Mar 31, 2024 | -$13.00M | $222.00M | $169.00M | $157.00M | $40.00M |